Immunosep – Precision Immunotherapy to Improve Sepsis Outcomes

Precision Immunotherapy to Improve Sepsis Outcomes Giamarellos-Bourboulis. JAMA 2025. doi:10.001/jama.2025.24175 Clinical Question In patients with sepsis, does immunotherapy (using either anakinra or human interferon gamma) that is tailored to the type of immune dysregulation lead to a reduction in organ dysfunction at day 9? Background Sepsis can involve a dysregulated immune response to an infection (SIDP, sepsis induced immune dysfunction) […]

Continue reading »

RECOVERY REGEN-COV

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial @PeterHorby. medRxiv pre-print 2021 doi: https://doi.org/10.1101/2021.06.15.21258542 Clinical Question In hospitalised patients with COVID-19, does the addition of monoclonal antibodies REGEN-COV (carsirivimab & imdevimab) to standard care, compared with standard care alone, improve 28 day mortality? Background Monoclonal antibodies have been shown to be […]

Continue reading »